# A Prospective, Randomized, Open, Phase II Clinical Study of Chidamide in Combination with Camrelizumab and Apatinib for Advanced Esophageal Cancer

> **NCT06745193** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Peking University** · enrollment: 63 (estimated)

## Conditions studied

- Advanced Esophageal Carcinoma

## Interventions

- **DRUG:** chidamide+Camrelizumab+Apatinib
- **DRUG:** Irinotecan or Docetaxel or Paclitaxel

## Key facts

- **NCT ID:** NCT06745193
- **Lead sponsor:** Peking University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-02-01
- **Primary completion:** 2027-02-01
- **Final completion:** 2028-02-01
- **Target enrollment:** 63 (ESTIMATED)
- **Last updated:** 2024-12-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06745193

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06745193, "A Prospective, Randomized, Open, Phase II Clinical Study of Chidamide in Combination with Camrelizumab and Apatinib for Advanced Esophageal Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06745193. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*